EntreMed's ENMD-2076 Awarded Patent In China

EntreMed, Inc.

, a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.  The granted claims are directed to ENMD-2076, covering composition of matter and uses to treat various cancers.  The patent is part of EntreMed's broad intellectual property portfolio for ENMD-2076. (Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) "We are very pleased with the issuance of this patent in China for ENMD-2076," said Ken K. Ren, Ph.D., the Company's Chief Executive Officer.  "This patent provides intellectual property protection for ENMD-2076 in a market that is experiencing tremendous growth and of which we intend to capitalize on.  The issuance of this patent broadens our existing international patent estate for ENMD-2076 and also confirms the Chinese State Intellectual Property Office's recognition that ENMD-2076 represents new and inventive chemical structures."  ENMD-2076 has completed and shown activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is completing a Phase 2 trial for ovarian cancer.  A Phase 2 triple-negative breast cancer trial at the University of Colorado and Indiana